Mechanisms involved in morphine-induced activation of synaptosomal Na+,K+-ATPase

Brain Research

Volumn 957, Issue 2, 2002, Pages 311-319

  Masocha, Willias ^a   González, Luis Gerardo ^a   Baeyens, José Manuel ^a   Agil, Ahmad ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Funaltrexamine; Opioid receptor; Buprenorphine; Gi o protein; Morphine; Na+,K+ ATPase; Naloxonazine; Naloxone; Pertussis toxin; Synaptosome

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA FUNALTREXAMINE; BUPRENORPHINE; GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; MU OPIATE RECEPTOR; NALOXONAZINE; NALOXONE; OUABAIN; PERTUSSIS TOXIN;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN MEMBRANE; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BRAIN; BUPRENORPHINE; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GTP-BINDING PROTEINS; MICE; MORPHINE; NA(+)-K(+)-EXCHANGING ATPASE; NARCOTIC ANTAGONISTS; OUABAIN; PERTUSSIS TOXIN; PRESYNAPTIC TERMINALS; RECEPTORS, OPIOID, MU; SYNAPTOSOMES;

EID: 0037073593     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03663-6     Document Type: Article

References (45)

1. Acuña Castroviejo D., Del Aguila C.M., Fernandez B., Gomar M.D., Castillo J.L. Characterization of ouabain high-affinity binding to rat cerebral cortex. Modulation by melatonin. Eur. J. Pharmacol. 226:1992;59-66.
2. Adams J.U., Paronis C.A., Holtzman S.G. Assessment of relative intrinsic activity of μ-opioid analgesics in vivo by using β-funaltrexamine. J. Pharmacol. Exp. Ther. 255:1990;1027-1032.
3. +-ATPase activity: physiological relevance and cellular mechanisms. Am. J. Physiol. 265:1993;F743-F755.
4. +-ATPase. Clin. Exp. Hypertens. 20:1998;465-480.
5. Birnbaumer L., Brown A.M. Ionic channels and their regulation by G protein subunits. Annu. Rev. Physiol. 52:1990;197-213.
6. +-ATPase α-subunit isoform distribution and abundance in guinea-pig longitudinal muscle/myenteric plexus after exposure to morphine. Brain Res. 931:2002;186-193.
7. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. 48:1991;1991-2003.
8. Desaiah D., Ho I.K. Effect of morphine on mice brain ATPase activities. Biochem. Pharmacol. 26:1977;89-92.
9. Dhawan B.N., Cesselin F., Ragghubir R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 48:1996;567-592.
10. Fiske C.H., Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66:1925;375-400.
11. Freissmuth M., Waldhoer M., Bofill-Cardona E., Nanoff C. G protein antagonists. Trends Pharmacol. Sci. 20:1999;237-245.
12. 3H]glibenclamide binding to forebrain membranes during morphine tolerance. Eur. J. Pharmacol. 418:2001;29-37.
13. Hahn E.F., Pasternak G.W. Naloxonazine, a potent, long-lasting inhibitor of opiate binding sites. Life Sci. 31:1982;1385-1388.
14. +-adenosine triphosphatase activity in frog spinal cord membrane fractions. Neurosci. Lett. 59:1985;291-295.
15. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
16. 3H]ouabain binding in the rat central nervous system. J. Neurochem. 44:1985;1709-1715.
17. +-ATPase in renal proximal tubules via the cAMP pathway. Eur. J. Pharmacol. 321:1997;259-263.
18. 3H]naloxonazine to rat brain membranes. Mol. Pharmacol. 26:1984;477-483.
19. Kong J.Q., Meng J., Biser P.S., Fleming W.W., Taylor D.A. Cellular depolarization of neurons in the locus coeruleus region of the guinea pig associated with the development of tolerance to opioids. J. Pharmacol. Exp. Ther. 298:2001;909-916.
20. Ling G.S., Simantov R., Clark J.A., Pasternak G.W. Naloxonazine actions in vivo. Eur. J. Pharmacol. 129:1986;33-38.
21. Lingrel J.B., Argüello J.M., Van Huysse J., Kuntzweiler T.A. Cation and cardiac glycoside binding sites of the Na,K-ATPase. Ann. NY Acad. Sci. 834:1997;194-206.
22. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
23. +-ATPase activity by dynorphin-A and ethylketocyclazocine. Life Sci. 42:1988;461-468.
24. +-ATPase in the antinociception induced by μ-opioid receptor agonists. Methods Find. Exp. Clin. Pharmacol. 22:2000;485.
25. 1A receptor expressed in HeLa cells. J. Clin. Invest. 86:1990;1799-1805.
26. Nagy A., Delgado-Escueta A.V. Rapid preparation of synaptosomes from mammalian brain using nontoxic isoosmotic gradient material (Percoll). J. Neurochem. 43:1984;1114-1123.
27. +-ATPase from homogenate of synaptosomes and of synaptic membrane of rat cerebral cortex. Brain Res. 510:1990;92-96.
28. North R.A. Drug receptors and the inhibition of nerve cells. Br. J. Pharmacol. 98:1989;13-28.
29. +-ATPase activity in synergism with neuropeptide Y. Diabetologia. 39:1996;199-205.
30. Parenti M., Tirone F., Giagnoni G., Pecora N., Parolaro D. Pertussis toxin inhibits the antinociceptive action of morphine in the rat. Eur. J. Pharmacol. 124:1986;357-359.
31. Pasternak G.W. Insights into mu opioid pharmacology. The role of mu opioid receptor subtypes. Life Sci. 68:2001;2213-2219.
32. Pasternak G.W., Wood P.L. Multiple mu opiate receptors. Life Sci. 38:1986;1888-1898.
33. Paul D., Bodnar R.J., Gistrak M.A., Pasternak G.W. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmacol. 168:1989;307-314.
34. 2 opioid actions. Life Sci. 48:1991;2005-2011.
35. Portoghese P.S., Larson D.L., Sayre L.M., Fries D.S., Takemori A.E. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J. Med. Chem. 23:1980;233-234.
36. Recht L.D., Pasternak G.W. Effects of beta-funaltrexamine on radiolabeled opioid binding. Eur. J. Pharmacol. 140:1987;209-214.
37. Sadrzadeh S.M., Vincenzi F.F., Hind T.R. Simultaneous measurement of multiple membrane ATPase in microtiter plates. J. Pharmacol. Methods. 30:1993;103-110.
38. 35S]GTP-γS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther. 285:1998;496-505.
39. Sharma P., Kaur G., Bhardwaj S.K., Kaur G. Role of opioidergic and monoaminergic neurotransmission in the GnRH release mechanism of EBP-primed OVX rats. Brain Res. Bull. 47:1998;81-86.
40. Takemori A.E., Larson D.L., Portoghese P.S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Eur. J. Pharmacol. 70:1981;445-451.
41. Therien A.G., Blostein R. Mechanisms of sodium pump regulation. Am. J. Physiol Cell Physiol. 279:2000;C541-C566.
42. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47:1995;848-854.
43. Ward S.J., Portoghese P.S., Takemori A.E. Pharmacological characterization in vivo of the novel opiate β-funaltrexamine. J. Pharmacol. Exp. Ther. 220:1982;494-498.
44. +-ATPase activity in murine LTK-cells. Mol. Pharmacol. 46:1996;373-378.
45. Zimmerman D.M., Leander J.D., Reel J.K., Hynes M.D. Use of β-funaltrexamine to determine μ opioid receptor involvement in the analgesic activity of various opioid ligands. J. Pharmacol. Exp. Ther. 241:1987;374-378.